Onxeo: Disclosure of total number of voting rights and number of shares in the capital at June 30, 2015

PARIS--()--Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):

         
Date   Total number of outstanding shares   Total number of voting rights
June 30, 2015   40, 544, 204   Theoretical number of voting rights: 40, 544, 204
(including treasury shares)

Number of real voting rights: 40, 530, 204 (without treasury shares)

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive complete results of the Phase II trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Contacts

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 1 44 54 36 66
onxeo@alizerp.com

Release Summary

Disclosure of total number of voting rights and number of shares in the capital at June 30, 2015

Contacts

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 1 44 54 36 66
onxeo@alizerp.com